Avexa Limited
Description Avexa Limited, a biotechnology company, engages in the discovery, development, and commercialization of anti-infective pharmaceutical medicines for the treatment of human infectious diseases. The companys research programs primarily focus on the discovery of medicines for the treatment of the diseases caused by human immunodeficiency virus (HIV) and vancomycin- and methicillin-resistant bacteria. Its principal projects include apricitabine, a nucleoside reverse transcriptase inhibitor for the treatment of HIV infection; and an HIV integrase inhibitor program. The company, through its license agreement with Valevia Pharmaceuticals GmbH, also develops AVX13616, an anti-bacterial lead compound for antibiotic-resistant bacterial infections. The company was founded in 2004 and is based in Richmond, Australia. To view the detailed information, you need to SUBSCRIBE with us. |
 |